ChemicalBook > CAS DataBase List > WNK inhibitor 12

WNK inhibitor 12

Product Name
WNK inhibitor 12
CAS No.
2123483-49-6
Chemical Name
WNK inhibitor 12
Synonyms
WNK-476;WNK 476;WNKIN12;WNK IN 12;WNK-IN-12;WNK-IN-11-d3;WNK inhibitor 12;WNK IN 11 d3,WNK-IN-11-d-3,WNKIN11d3
CBNumber
CB94668672
Molecular Formula
C21H21Cl2N5OS
Formula Weight
462.39
MOL File
2123483-49-6.mol
More
Less

WNK inhibitor 12 Property

storage temp. 
Store at -20°C
form 
Solid
color 
Off-white to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

WNK inhibitor 12 Chemical Properties,Usage,Production

Uses

WNK-IN-11-d3 is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11-d3 is effective at regulating cardiovascular homeostasis[1].

Biological Activity

WNK-IN-11 D3 is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11 D3 is effective at regulating cardiovascular homeostasis[1]. WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability[1].WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice[1].WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg[1].WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload[1].

in vivo

WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability[1].
WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice[1].
WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg[1].
WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload[1].

Animal Model:Sprague?Dawley rats[1]
Dosage:1.5 mg/kg
Administration:P.o.
Result:Showed an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.
Animal Model:FVB mice[1]
Dosage:30 mg/kg
Administration:P.o.
Result:Showed significant reductions in systolic blood pressure (SBP) vs untreated mice.
Animal Model:FVB mice[1]
Dosage:0~100 mg/kg
Administration:P.o.
Result:Induced dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.

References

[1]. Yamada K, Levell J, Yoon T, et al. Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models. J Med Chem. 2017;60(16):7099-7107.

WNK inhibitor 12 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

WNK inhibitor 12 Suppliers

Guangzhou Baide Biotechnology Co., Ltd.
Tel
18925065404
Country
CHINA
ProdList
168
Advantage
58

2123483-49-6, WNK inhibitor 12Related Search:


  • WNK inhibitor 12
  • WNK 476
  • WNK-476
  • WNK IN 12
  • WNKIN12
  • WNK-IN-12
  • WNK-IN-11-d3
  • WNK IN 11 d3,WNK-IN-11-d-3,WNKIN11d3
  • 2123483-49-6